New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature Review
Despite improvements in the treatment of patients with newly diagnosed multiple myeloma (MM) through the introduction of new drugs and high-dose chemotherapy with autologous hematopoietic stem cell transplantation, relapses are still inevitable in all patients. The use of immunomodulatory agents (th...
Main Author: | |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Practical Medicine Publishing House
2017-10-01
|
Series: | Kliničeskaâ onkogematologiâ |
Subjects: | |
Online Access: | http://bloodjournal.ru/wp-content/uploads/2017/10/1_1.pdf |
id |
doaj-4d74f5f3f4974ce9ba3274e92d3987bd |
---|---|
record_format |
Article |
spelling |
doaj-4d74f5f3f4974ce9ba3274e92d3987bd2020-11-25T00:36:41ZrusPractical Medicine Publishing HouseKliničeskaâ onkogematologiâ1997-69332500-21392017-10-0110442543410.21320/2500-2139-2017-10-4-425-434New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature ReviewOM Votyakova0NN Blokhin National Medical Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478Despite improvements in the treatment of patients with newly diagnosed multiple myeloma (MM) through the introduction of new drugs and high-dose chemotherapy with autologous hematopoietic stem cell transplantation, relapses are still inevitable in all patients. The use of immunomodulatory agents (thalidomide, lenalidomide) and proteasome inhibitor bortezomib has improved the treatment of relapses. However, the disease progression lead to repeated relapses and eventually refractory MM. For these patients new therapeutic strategies are needed, including the development of more effective drugs within the existing classes and the study of new combinations, as well as searching new targets for the treatment of MM. We present the key clinical data on the efficacy and safety of the most promising proteasome inhibitors (carfilzomib, ixazomib), new generation immunomodulatory drug pomalidomide, and monoclonal antibodies (daratumumab and elotuzumab).http://bloodjournal.ru/wp-content/uploads/2017/10/1_1.pdfproteasome inhibitorsimmunomodulatory medicationmonoclonal antibodiesmultiple myeloma |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
OM Votyakova |
spellingShingle |
OM Votyakova New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature Review Kliničeskaâ onkogematologiâ proteasome inhibitors immunomodulatory medication monoclonal antibodies multiple myeloma |
author_facet |
OM Votyakova |
author_sort |
OM Votyakova |
title |
New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature Review |
title_short |
New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature Review |
title_full |
New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature Review |
title_fullStr |
New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature Review |
title_full_unstemmed |
New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature Review |
title_sort |
new possibilities of treatment for relapsed/refractory multiple myeloma: a literature review |
publisher |
Practical Medicine Publishing House |
series |
Kliničeskaâ onkogematologiâ |
issn |
1997-6933 2500-2139 |
publishDate |
2017-10-01 |
description |
Despite improvements in the treatment of patients with newly diagnosed multiple myeloma (MM) through the introduction of new drugs and high-dose chemotherapy with autologous hematopoietic stem cell transplantation, relapses are still inevitable in all patients. The use of immunomodulatory agents (thalidomide, lenalidomide) and proteasome inhibitor bortezomib has improved the treatment of relapses. However, the disease progression lead to repeated relapses and eventually refractory MM. For these patients new therapeutic strategies are needed, including the development of more effective drugs within the existing classes and the study of new combinations, as well as searching new targets for the treatment of MM. We present the key clinical data on the efficacy and safety of the most promising proteasome inhibitors (carfilzomib, ixazomib), new generation immunomodulatory drug pomalidomide, and monoclonal antibodies (daratumumab and elotuzumab). |
topic |
proteasome inhibitors immunomodulatory medication monoclonal antibodies multiple myeloma |
url |
http://bloodjournal.ru/wp-content/uploads/2017/10/1_1.pdf |
work_keys_str_mv |
AT omvotyakova newpossibilitiesoftreatmentforrelapsedrefractorymultiplemyelomaaliteraturereview |
_version_ |
1725304224902807552 |